Posted by Michael Wonder on 02 Nov 2022
Ardelyx collaboration partner, Kyowa Kirin, announces submission of new drug application for tenapanor for hyperphosphataemia in Japan
31 October 2022 - Ardelyx today announced that its collaboration partner in Japan, Kyowa Kirin, has submitted a new drug application to the Japanese MHLW for tenapanor for the improvement of hyperphosphataemia in adult patients with chronic kidney disease on dialysis.
The new drug application is supported by data from four Phase 3 clinical trials, conducted by Kyowa Kirin in Japan in patients with hyperphosphataemia on maintenance dialysis.
